Literature DB >> 30782296

Exploration of pro-apoptotic effect of Thymoquinone on oral squamous cell carcinoma cells through PI3K/Akt signaling pathway.

Xun Ren1, Wei Luo1.   

Abstract

Oral squamous cell carcinoma (OSCC) is the sixth most prevalent cancer type in the world, with a 5-year survival rate of only 40% to 50%. Finding effective anti-tumor drug candidates is quite necessary for the progression of OSCC therapy. In this study, the role of Thymoquinone (TQ) in OSCC cells was studied. It was confirmed that TQ can inhibit the proliferation, migration and invasion of KB cells, and can also achieve apoptosis by inhibiting the activation of PI3K/Akt pathway. Therefore, TQ is an effective candidate for the treatment of OSCC.

Entities:  

Keywords:  Oral squamous cell carcinoma; PI3K-Akt.; Pro-apoptotic; Thymoquinone

Mesh:

Substances:

Year:  2019        PMID: 30782296

Source DB:  PubMed          Journal:  Cell Mol Biol (Noisy-le-grand)        ISSN: 0145-5680            Impact factor:   1.770


  5 in total

Review 1.  Thymoquinone, as a Novel Therapeutic Candidate of Cancers.

Authors:  Belal Almajali; Hamid Ali Nagi Al-Jamal; Wan Rohani Wan Taib; Imilia Ismail; Muhammad Farid Johan; Abd Almonem Doolaanea; Wisam Nabeel Ibrahim
Journal:  Pharmaceuticals (Basel)       Date:  2021-04-16

Review 2.  Role of PI3K/AKT pathway in squamous cell carcinoma with an especial focus on head and neck cancers.

Authors:  Soudeh Ghafouri-Fard; Ali Noie Alamdari; Yashar Noee Alamdari; Atefe Abak; Bashdar Mahmud Hussen; Mohammad Taheri; Elena Jamali
Journal:  Cancer Cell Int       Date:  2022-08-13       Impact factor: 6.429

3.  Protective Effects of Thymoquinone, an Active Compound of Nigella sativa, on Rats with Benzo(a)pyrene-Induced Lung Injury through Regulation of Oxidative Stress and Inflammation.

Authors:  Mohammad A Alzohairy; Amjad Ali Khan; Mohammed A Alsahli; Saleh A Almatroodi; Arshad Husain Rahmani
Journal:  Molecules       Date:  2021-05-27       Impact factor: 4.411

Review 4.  Recent Findings on Thymoquinone and Its Applications as a Nanocarrier for the Treatment of Cancer and Rheumatoid Arthritis.

Authors:  Ravi Raj Pal; Vasundhara Rajpal; Priya Singh; Shubhini A Saraf
Journal:  Pharmaceutics       Date:  2021-05-22       Impact factor: 6.321

5.  Gene Expression Profiling and Protein Analysis Reveal Suppression of the C-Myc Oncogene and Inhibition JAK/STAT and PI3K/AKT/mTOR Signaling by Thymoquinone in Acute Myeloid Leukemia Cells.

Authors:  Belal Almajali; Muhammad Farid Johan; Abdullah Saleh Al-Wajeeh; Wan Rohani Wan Taib; Imilia Ismail; Maysa Alhawamdeh; Nafe M Al-Tawarah; Wisam Nabeel Ibrahim; Futoon Abedrabbu Al-Rawashde; Hamid Ali Nagi Al-Jamal
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.